This contract expires in 132 days (Nov 17, 2026).
THE INSTITUTE FOR CANCER RESEARCH - TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER
Key Details
Description
TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER
Context & Analysis
On Nov 24, 2025, Department of Health and Human Services obligated $1,237,620 to THE INSTITUTE FOR CANCER RESEARCH for task order title: next generation gp130/il-6/stat3 inhibitors for the prevention of colitis-associated colorectal cancer. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in PHILADELPHIA, PA. The contract is scheduled through Nov 17, 2026 — approximately 4 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.